Amylin (Cagrilintide) — a new path to weight control
Cagrilintide — a long-acting amylin hormone analogue (Novo Nordisk molecule, PeptoLabs product). Separate from GLP-1 mechanism — can be combined with Mounjaro or Ozempic. Up to -22.7% weight with CagriSema.
monotherapy (Phase 2, 26 weeks)
What is Amylin / Cagrilintide?
Cagrilintide · Amilin 20 mg · PeptoLabs
Cagrilintide is a long-acting analogue of the human amylin hormone. The molecule was developed by Novo Nordisk (Denmark), and the Amilin 10/20 mg product is manufactured by PeptoLabs.
Unlike GLP-1 agonists (Ozempic, Mounjaro), Cagrilintide acts through amylin receptors — an entirely different appetite regulation pathway. Amylin is a natural hormone produced by pancreatic β-cells alongside insulin during meals.
Cagrilintide is available as an injector pen (10 mg and 20 mg by PeptoLabs). Administered subcutaneously once a week, with gradual dose escalation from 1 mg to optimal (max 6 mg/week). Can be combined with GLP-1 agonists for synergistic effect — as in CagriSema by Novo Nordisk (up to −22.7% weight loss).
Key advantage: Cagrilintide acts through amylin receptors — a separate from GLP-1 pathway for appetite control. This allows combining it with Mounjaro or Ozempic to enhance results.
How Amylin (Cagrilintide) works for weight loss
Cagrilintide mimics the natural amylin hormone — a separate from GLP-1 pathway for appetite control.
Appetite suppression
Acts on the area postrema and nucleus tractus solitarius in the brainstem — a separate from GLP-1 hunger control center.
Gastric slowing
Slows rapid gastric emptying after meals. Food is digested more slowly — fullness lasts significantly longer.
Glucagon control
Reduces postprandial glucagon secretion, decreasing blood sugar fluctuations and reducing sugar cravings.
Amylin + GLP-1 synergy
Cagrilintide acts through amylin receptors, while GLP-1 agonists act through GLP-1 receptors. Two different appetite control pathways that can be combined.
Novo Nordisk developed CagriSema (Cagrilintide + semaglutide), which showed weight loss of up to −22.7% over 68 weeks — significantly more than semaglutide alone (-15.8%).
Combination even at low doses outperforms high-dose monotherapy
| Parameter | Cagri 1.2 mg + Sema 1.2 mg | Sema 2.4 mg | Cagri 2.4 mg |
|---|---|---|---|
| HbA1c ↓ | −2.2% | −1.8% | −0.9% |
| Weight loss | −15.6% | −5.1% | −8.1% |
| Fasting glucose ↓ | −3.3 | −2.5 | −1.7 |
Combination at 1.2 mg each achieves better results than 2.4 mg of either alone — with lower total dose and fewer side effects.
Which product is right for you?
Cagrilintide, Mounjaro or Ozempic? Take an 8-step survey and get a personalized recommendation.
Start the test →Which product is right for you?
Cagrilintide, Mounjaro or Ozempic? Take an 8-step survey and get a personalized recommendation.
No obligations. Answer immediately after completion.
Who is Amylin (Cagrilintide) suitable for
Recommended
- BMI ≥ 27 with desire to lose weight
- Insufficient effect from GLP-1 alone
- Desire to try a new mechanism
- Combination with Mounjaro or Ozempic
- Insulin resistance
Not recommended
- Pregnancy and breastfeeding
- Under 18 years of age
- Medullary thyroid cancer
- Acute pancreatitis
- Allergy to components
Not sure? Ask a DOZA specialist — free consultation.
Results and efficacy
Cagrilintide clinical data
In the Phase 2 study (706 participants, 26 weeks), Cagrilintide at 4.5 mg showed 10.8% weight loss vs 3.0% placebo.
In combination with semaglutide (CagriSema), REDEFINE-2 (3,417 participants, 68 weeks) demonstrated 22.7% weight loss — significantly exceeding semaglutide alone (15.8%).
Monotherapy advantages
- • New mechanism — separate from GLP-1
- • Convenient once-weekly dosing
- • Good tolerability
Combination advantages
- • Synergy of two appetite control pathways
- • Up to -22.7% weight with CagriSema
- • Can be combined with Mounjaro or Ozempic
Amylin / Cagrilintide (Amilin) dosage
Pens 10 and 20 mg. Start from 1 mg per week with gradual increase — specialist selects individually.
Cagrilintide (Amilin) — pens 10 and 20 mg by PeptoLabs. Start from 1 mg/week, gradual increase to optimal (max 6 mg/week). DOZA specialist selects individually.
Adaptation considerations
Cagrilintide is well tolerated. Most effects are mild and short-lived.
A DOZA specialist helps minimize any discomfort. Consultation — on Telegram.
Amylin is available in two formats
Choose the convenient option — original PeptoLabs product in both cases
Cagrilintide vs Mounjaro vs Ozempic
| Parameter | Cagrilintide | Mounjaro | Ozempic |
|---|---|---|---|
| Active ingredient | Cagrilintide | Tirzepatide | Semaglutide |
| Class | Amylin analogue | GLP-1 + GIP | GLP-1 |
| Efficacy (mono) | -10.8% | -22.5% | -15% |
| In combination | -22.7% (CagriSema) | — | -22.7% (CagriSema) |
| Frequency | 1× per week | 1× per week | 1× per week |
| Developer | Novo Nordisk / PeptoLabs | Eli Lilly | Novo Nordisk |
| GLP-1 combination | Yes | No | No |
Cagrilintide is the only amylin analogue that can be combined with GLP-1 to enhance the effect.
Sources
- • Lau DCW et al. (Lancet, 2021) — Cagrilintide Phase 2 study, 706 participants, 26 weeks, dose-dependent weight loss up to -10.8%
- • REDEFINE-2 (Lancet, 2024) — CagriSema (cagrilintide + semaglutide), 3417 participants, 68 weeks, -22.7% weight loss
- • Novo Nordisk: Cagrilintide — long-acting amylin analogue for obesity (Phase III clinical programme)
Frequently asked questions about Amylin (Cagrilintide)
Cagrilintide is a long-acting human amylin hormone analogue developed by Novo Nordisk. Unlike GLP-1 agonists (Ozempic, Mounjaro), it acts through a separate amylin receptor in the brain. Available as Amilin by PeptoLabs in 20 mg dose.
DOZA Specialist
Take a free test
2 minIn 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.